Treating inflammation with a combination of an ellagitannin and hydrogen peroxide

Abstract

The teachings provided herein generally relate to site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites. More particularly, the systems taught here include a phenolic compound bound to a reactive oxygen species, wherein the phenolic compound and the reactive oxygen species react at a target area in the presence of an oxidoreductase enzyme.

1 . A method of treating an inflammation in a subject, comprising:
 administering an effective amount of a binding system to a subject having an inflammation, the binding system comprising:
 an ellagitannin; and, 
 hydrogen peroxide; 
   wherein,
 the hydrogen peroxide is combined with the ellagitannin at a weight ratio that ranges from about 1:1000 to about 10:1 of the an extract to the hydrogen peroxide; and, 
 the administering inhibits, or ameliorates the symptoms of, the inflammation of the subject. 
   
     
     
         2 . The method of  claim 1 , wherein the administering of the binding system includes obtaining the binding system as a pharmaceutical formulation comprising the binding system of  claim 1  and a pharmaceutically acceptable excipient. 
     
     
         3 . The method of  claim 1 , wherein the ellagitannin is a punicalagin. 
     
     
         4 . The method of  claim 1 , wherein the binding system further comprises a catechin. 
     
     
         5 . The method of  claim 1 , wherein the binding system further comprises gallic acid, epigallic acid, or a combination thereof. 
     
     
         6 . The method of  claim 1 , wherein the ellagitannin is an extract of pomegranate. 
     
     
         7 . The method of  claim 4 , wherein the catechin is an extract of green tea. 
     
     
         8 . The method of  claim 1 , wherein the weight ratio of the ellagitannin to the hydrogen peroxide ranges from about 1:1 to about 1:50. 
     
     
         9 . The method of  claim 1 , wherein the administering further comprises obtaining a kit comprising the binding system, wherein the kit comprises a dry form of the binding system, as well as instructions for diluting the binding system for administration with suggested dilution factors for various target sites. 
     
     
         10 . A method of inhibiting a gastrointestinal-mediated autoimmune response in a subject, comprising:
 administering an effective amount of a binding system to a subject having a gastrointestinal-mediated autoimmune activity, the binding system comprising:
 an ellagitannin; and, 
 hydrogen peroxide; 
   wherein,
 the hydrogen peroxide is combined with the ellagitannin at a weight ratio that ranges from about 1:1000 to about 10:1 of the an extract to the hydrogen peroxide; and, 
 the administering inhibits, or ameliorates the symptoms of, the gastrointestinal-mediated autoimmune activity in the subject. 
   
     
     
         11 . The method of  claim 10 , wherein the administering of the binding system includes obtaining the binding system as a pharmaceutical formulation comprising the binding system of  claim 1  and a pharmaceutically acceptable excipient. 
     
     
         12 . The method of  claim 10 , wherein the ellagitannin is a punicalagin. 
     
     
         13 . The method of  claim 10 , wherein the binding system further comprises a catechin. 
     
     
         14 . The method of  claim 10 , wherein the binding system further comprises gallic acid, epigallic acid, or a combination thereof. 
     
     
         15 . The method of  claim 10 , wherein the ellagitannin is an extract of pomegranate. 
     
     
         16 . The method of  claim 13 , wherein the catechin is an extract of green tea. 
     
     
         17 . The method of  claim 10 , wherein the weight ratio of the ellagitannin to the hydrogen peroxide ranges from about 1:1 to about 1:50. 
     
     
         18 . The method of  claim 10 , wherein the administering further comprises obtaining a kit comprising the binding system, wherein the kit comprises a dry form of the binding system, as well as instructions for diluting the binding system for administration with suggested dilution factors for various target sites. 
     
     
         19 . A composition, comprising:
 an ellagitannin;   hydrogen peroxide; and,   a pharmaceutically acceptable carrier;   wherein,   the hydrogen peroxide is combined with the ellagitannin at a weight ratio that ranges from about 1:1000 to about 10:1 of the ellagitannin to the hydrogen peroxide.   
     
     
         20 . The composition of  claim 19 , wherein the ellagitannin is a punicalagin. 
     
     
         21 . The composition of  claim 19 , wherein the composition further comprises a catechin. 
     
     
         22 . The composition of  claim 19 , wherein the composition further comprises gallic acid, epigallic acid, or a combination thereof. 
     
     
         23 . The composition of  claim 19 , wherein the ellagitannin is an extract of pomegranate. 
     
     
         24 . A formulation comprising the composition of  claim 19  and a pharmaceutically acceptable excipient. 
     
     
         25 . The formulation of  claim 24 , wherein the weight ratio of the ellagitannin to the hydrogen peroxide ranges from about 1:1 to about 1:50. 
     
     
         26 . A kit for generating the composition of  claim 19 , wherein the kit comprises a dry form of the punicalagin and a dry form of a hydrogen peroxide generating material, as well as instructions for mixing the components for administration and suggested dilution factors for various target sites. 
     
     
         27 . A formulation, comprising:
 a punicalagin;   hydrogen peroxide; and,   a pharmaceutically acceptable excipient;   wherein,   the hydrogen peroxide is combined with the punicalagin at a weight ratio that ranges from about 1:1000 to about 10:1 of the an extract to the hydrogen peroxide.   
     
     
         28 . The formulation of  claim 27 , wherein the formulation further comprises a catechin. 
     
     
         29 . The formulation of  claim 27 , wherein the punicalagin is an extract of pomegranate. 
     
     
         30 . A kit for generating the formulation of  claim 27 , wherein the kit comprises a dry form of the punicalagin, a dry form of a hydrogen peroxide generating material, and the excipient, as well as instructions for mixing the components for administration and suggested dilution factors for various target sites.